This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Should First Trust Morningstar Dividend Leaders ETF (FDL) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for FDL
AbbVie (ABBV) Seeks Approval for Skyrizi for Ulcerative Colitis
by Zacks Equity Research
AbbVie's (ABBV) regulatory applications filed to the FDA and the EMA seeking approval for Skyrizi for ulcerative colitis are based on data from two phase III studies.
The Zacks Analyst Blog Highlights Procter & Gamble, AbbVie, The Walt Disney, HSBC Holdings and Duke Energy
by Zacks Equity Research
Procter & Gamble, AbbVie, The Walt Disney, HSBC Holdings and Duke Energy are part of the Zacks top Analyst Blog.
Investors Heavily Search AbbVie Inc. (ABBV): Here is What You Need to Know
by Zacks Equity Research
Zacks.com users have recently been watching AbbVie (ABBV) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Top Analyst Reports for Procter & Gamble, AbbVie & Walt Disney
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including The Procter & Gamble Company (PG), AbbVie Inc. (ABBV) and The Walt Disney Company (DIS).
Can AbbVie (ABBV) Protect Revenues After Humira Patent Loss?
by Zacks Equity Research
AbbVie's (ABBV) newer products, Skyrizi and Rinvoq, are performing extremely well and have the potential to make up for lost Humira revenues.
These 3 Large-Cap Pharma Stocks Have Been Red-Hot
by Derek Lewis
Large-cap pharmaceuticals have enjoyed buying pressure over the last month, delivering outsized gains to investors. And these three stocks have helped lead the charge.
Pharma Stock Roundup: FDA Okays PFE & JNJ Drugs, EU Approves ABBV's Migraine Drug
by Kinjel Shah
FDA approves Pfizer's (PFE) Elrexfio (elranatamab) for RRMM and J&J's (JNJ) oral combination tablet, Akeega to treat BRCA-positive mCRPC. European Commission approves AbbVie's (ABBV) Aquipta for migraine.
AbbVie (ABBV) Gets EU Approval for Migraine Prevention Drug
by Zacks Equity Research
Following the approval, AbbVie's (ABBV) Aquipta is the first and the only oral CGRP receptor antagonist approved in the EU to prevent episodic and chronic migraines.
3 Dividend Aristocrats Positively Surprising Investors
by Derek Lewis
The bulk of the Q2 season is in the rearview mirror, but the quarterly results from these 3 Dividend Aristocrats shouldn't be ignored.
Ironwood's (IRWD) Reports Q2 Loss, Linzess Volume Rises
by Zacks Equity Research
Ironwood (IRWD) reports loss for second-quarter 2023. The top line increases year over year, driven by growth in Linzess collaboration revenues.
Amgen (AMGN) Q2 Earnings Beat Estimates, 2023 View Raised
by Zacks Equity Research
Amgen (AMGN) beats Q2 estimates for earnings and sales. It slightly raises its earnings and sales guidance for 2023.
Amgen (AMGN) to Report Q2 Earnings: Here's What to Expect
by Zacks Equity Research
Volume growth from Amgen's (AMGN) key drugs like Prolia, Repatha and Evenity, among others, is expected to have been partially offset by biosimilar/generic competition for mature drugs.
Pharma Stock Roundup: AZN, SNY, ABBV Q2 Results, MRK, MRNA Cancer Jab in Phase III
by Kinjel Shah
AstraZeneca (AZN), Sanofi (SNY) and AbbVie (ABBV) announce second-quarter results.
AbbVie (ABBV) Beats on Q2 Earnings & Sales, Raises '23 View
by Zacks Equity Research
AbbVie's (ABBV) second-quarter 2023 earnings and sales beat estimates. The company raises its EPS guidance. Stock rises post the announcement.
Compared to Estimates, AbbVie (ABBV) Q2 Earnings: A Look at Key Metrics
by Zacks Equity Research
While the top- and bottom-line numbers for AbbVie (ABBV) give a sense of how the business performed in the quarter ended June 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
AbbVie (ABBV) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
AbbVie (ABBV) delivered earnings and revenue surprises of 4.30% and 2.54%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
The Zacks Analyst Blog Highlights Toyota, Deere, Starbucks, AbbVie and DexCom
by Zacks Equity Research
Toyota, Deere, Starbucks, AbbVie and DexCom are included in this Analyst Blog.
Q2 Earnings Season Scorecard and Analyst Reports for Toyota, Deere & Starbucks
by Sheraz Mian
Today's Research Daily features a real-time update on the Q2 earnings season, in addition to featuring updated reports on Toyota Motor(TM), Deere & Company (DE) and Starbucks (SBUX).
Will AbbVie's (ABBV) New Drugs Make Up for Low Humira Sales?
by Zacks Equity Research
In its Q2 earnings results, AbbVie's (ABBV) Skyrizi and Rinvoq sales are expected to have made up for the declining Humira sales following the loss of U.S. exclusivity.
Earnings Preview: Pfizer (PFE) Q2 Earnings Expected to Decline
by Zacks Equity Research
Pfizer (PFE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Should You Invest in the Invesco Dynamic Pharmaceuticals ETF (PJP)?
by Zacks Equity Research
Sector ETF report for PJP
Zacks Investment Ideas feature highlights: Chipotle Mexican Grill, Visa and AbbVie
by Zacks Equity Research
Chipotle Mexican Grill, Visa and AbbVie have been highlighted in this Investment Ideas article.
3 Non-Tech Reports to Watch This Week
by Derek Lewis
While many remain focused on tech, there are several other notable quarterly reports scheduled to come this week, including these three.
Is Invesco Dynamic Large Cap Value ETF (PWV) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for PWV